Low-dose radiation plus targeted pill for MALT lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of a low dose of radiation and an oral targeted drug (orelabrutinib) for people with early-stage MALT lymphoma. The goal is to see if adjusting the treatment based on your response can be effective and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of MALT lymphoma (a slow-growing type of B-cell lymphoma).
- Your lymphoma must be in an early stage (stage I or II), meaning it is limited to one or a few nearby areas.
- You must be able to swallow tablets on your own.
- You cannot have had prior cancer treatment like radiation, chemotherapy, or targeted therapy for MALT lymphoma.
- You need to have adequate organ function, which will be checked with blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining very low-dose radiation therapy with a targeted drug called orelabrutinib (a type of cancer-fighting protein inhibitor) as a first treatment for early-stage MALT lymphoma, a slow-growing blood cancer. The goal is to see if this combination can shrink or control the cancer with fewer side effects than standard chemotherapy.
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
This trial tests a targeted drug called orelabrutinib for people with a specific type of stomach lymphoma that is linked to an active H. pylori infection. The goal is to see if the drug can help shrink or control the lymphoma.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Hear when a new Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.